Anticoagulation in Management of Antiphospholipid Antibody Syndrome in Pregnancy

Clinics in Laboratory Medicine

Volumn 33, Issue 2, 2013, Pages 367-376

  Lockshin, Michael D ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Anticoagulation; Antiphospholipid antibody; Lupus anticoagulant; Pregnancy; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FETUS DEATH; HIGH RISK POPULATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; PREDICTION; PREECLAMPSIA; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 84878181344     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2013.01.001     Document Type: Review

References (56)

1. Wassermann A., Neisser A., Bruck C. Eine serodiagnostische Reaktion bei Syphilis. Deutsche medicinische Wochenschrift, Berlin 1906, 32:745-746.
2. Nielsen H.A., Reyn A. The Treponema pallidum immobilization test. Bull World Health Organ 1956, 14:263-288.
3. Conley C.L., Hartmann R.C. A hemorrhagic disorder caused by circulating anticoagulants in patients with disseminated lupus erythematosus. J Lab Clin Invest 1952, 31:621-622.
4. Mueh J.R., Herbst K.D., Rapaport S.I. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980, 92:156-159.
5. Bowie E.J., Thompson J.H., Pascuzzi C.A., et al. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963, 62:416-430.
6. Thiagarajan P., Shapiro S.S., De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980, 66:397-405.
7. Nilsson I.M., Åstedt B., Hedner U., et al. Intrauterine death and circulating anticoagulant (" antithromboplastin" ). Acta Med Scand 1975, 197:153-159.
8. Soulier J.P., Boffa M.C. Avortements á répétition, thromboses et anticoagulant circulant anti-thromboplastine: trois observations. Nouv Presse Med 1980, 9:859-864.
9. Firkin B.G., Howard M.A., Radford N. Possible relationship between lupus inhibitor and recurrent abortion in young women. Lancet 1980, 2:366.
10. Abramowsky C.R., Vegas M.E., Swinehart G., et al. Decidual vasculopathy of the placenta in lupus erythematosus. N Engl J Med 1980, 303:668-672.
11. Carreras L.O., Defreyn G., Machin S.J., et al. Arterial thrombosis, intrauterine death and " lupus" anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981, 1:244-246.
12. De Wolf F., Carreras L.O., Moerman P., et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss and a lupus anticoagulant. Am J Obstet Gynecol 1982, 142:829-834.
13. Hughes G.R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983, 287(6399):1088-1089.
14. Lubbe W.F., Palmer S.J., Butler W.S., et al. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet 1983, 1:1361-1363.
15. Reece E.A., Romero R., Clyne L.P., et al. Lupus-like anticoagulant in pregnancy. Lancet 1984, 1:344-345.
16. Gårdlund B. The lupus inhibitor in thromboembolic disease and intrauterine death in the absence of systemic lupus. Acta Med Scand 1984, 215:293-298.
17. Harris E.N., Gharavi A.E., Boey M.L., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983, 2:1211-1214.
18. Galli M., Comfurius P., Maassen C., et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 1990, 335:1544-1547.
19. McNeil H.P., Simpson R.J., Chesterman C.N., et al. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: b2 Glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990, 87:4120-4124.
20. Allen K.L., Fonseca F.V., Betapudi V., et al. A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood 2011, 119:884-893.
21. Mulla M.J., Brosens J.J., Chamley L.W., et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol 2009, 62:96-111.
22. Salmon J.E., Girardi G., Lockshin M.D. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol 2007, 3:140-147.
23. Erkan D., Bateman H., Lockshin M.D. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Lupus 1999, 8:560-564.
24. Amengual O., Atsumi T., Koike T. Pathophysiology of thrombosis and potential targeted therapies in antiphospholipid syndrome. Curr Vasc Pharmacol 2011, 9:606-618.
25. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226.
26. Ribeiro S.L., Pereira H.L., Silva N.P., et al. Anti-β2-glycoprotein I antibodies are highly prevalent in a large number of Brazilian leprosy patients. Acta Reumatol Port 2011, 36:30-37.
27. Levy R.A., de Meis E., Pierangeli S. An adapted ELISA method for differentiating pathogenic from nonpathogenic aPL by a beta 2 glycoprotein I dependency anticardiolipin assay. Thromb Res 2004, 114:573-577.
28. Han C.S., Mulla M.J., Brosens J.J., et al. Aspirin and heparin effect on basal and antiphospholipid antibody modulation of trophoblast function. Obstet Gynecol 2011, 118:1021-1028.
29. Meroni P.L., Borghi M.O., Raschi E., et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7:330-339.
30. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999, 42:1309-1311.
31. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
32. Erkan D., Lockshin M.D. Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010, 19:424-427.
33. Meroni P.L., Raschi E., Grossi C., et al. Obstetric and vascular APS: same autoantibodies but different diseases?. Lupus 2012, 21:708-710.
34. Lockshin M.D., Druzin M.L., Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989, 160:439-444.
35. Cowchock E.S., Reece E.A., Balababan D., et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low dose heparin treatment. Am J Obstet Gynecol 1992, 166:1313-1323.
36. Bradley L.A., Palomaki G.E., Bienstock J., et al. Can Factor V Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes?: results from a targeted evidence-based review. Genet Med 2012, 14:39-50.
37. Lockshin M.D., Druzin M.L., Goei S., et al. Antibody to cardiolipin predicts fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985, 313:152-156.
38. Branch D.W., Scott J.R., Kochenour N.K., et al. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985, 313:1322-1326.
39. Rai R., Cohen H., Dave M., et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314:253-257.
40. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996, 174:1584-1589.
41. Kutteh W.H., Ermel L.D. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996, 35:402-407.
42. Farquharson R.G., Quenby S., Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100:408-413.
43. Manuck T., Branch D.W., Lai Y., et al. Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for factor V Leiden. J Reprod Immunol 2010, 85:180-185.
44. Cohn D.M., Goddijn M., Middeldorp S., et al. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost 2010, 8:2208-2213.
45. Laskin C.A., Spitzer K.A., Clark C.A., et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009, 36:279-287.
46. Check J.H. The use of heparin for preventing miscarriage. Am J Reprod Immunol 2012, 67:326-333.
47. Salmon J.E., Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 2008, 77:51-56.
48. Erkan D., Yazici Y., Peterson M.G., et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002, 41:924-929.
49. Ioannou Y., Rahman A. Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome. Lupus 2010, 19:400-405.
50. Ruffatti A., Tonello M., Visentin M.S., et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011, 50:1684-1689.
51. Lockshin M.D., Kim M., Laskin C.A., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012, 64:2311-2318.
52. Gelber S.E., Salmon J.E. Autoimmunity: effectiveness of treatments for pregnant women with APS. Nat Rev Rheumatol 2010, 6:187-189.
53. Shapira I., Andrade D., Allen S.L., et al. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012, 64:2719-2723.
54. de la Torre Y.M., Pregnolato F., D'Amelio F., et al. Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. J Autoimmun 2012, 38:J209-J215.
55. Erkan D., Lockshin M.D. New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol 2009, 5:160-170.
56. Pierangeli S.S., Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?. Lupus 2010, 19:475-485.